Please use this identifier to cite or link to this item: https://hdl.handle.net/10923/23949
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMALUF, FERNANDO C.-
dc.contributor.authorSCHUTZ, FABIO A.-
dc.contributor.authorCRONEMBERGER, EDUARDO H.-
dc.contributor.authorLUZ, MURILO DE A.-
dc.contributor.authorMARTINS, SUELEN P.S.-
dc.contributor.authorMUNIZ, DAVID Q.B.-
dc.contributor.authorBASTOS, DIOGO A.-
dc.contributor.authorCÁRCANO, FLAVIO M.-
dc.contributor.authorSMALETZ, OREN-
dc.contributor.authorSOARES, ANDREY-
dc.contributor.authorPEIXOTO, FÁBIO A.-
dc.contributor.authorGOMES, ANDREA J.-
dc.contributor.authorCRUZ, FELIPE M.-
dc.contributor.authorFRANKE, FABIO A.-
dc.contributor.authorHERCHENHORN, DANIEL-
dc.contributor.authorDOS SANTOS, TELMA M.-
dc.contributor.authorFABRICIO, VANESSA DE C.-
dc.contributor.authorGIDEKEL, ROSEMARIE-
dc.contributor.authorWERUTSKY, GUSTAVO-
dc.contributor.authorDE JESUS, RAFAELA G.-
dc.contributor.authorSOUZA, VINICIUS C.-
dc.contributor.authorAndré Poisl Fay-
dc.date.accessioned2023-03-29T18:59:39Z-
dc.date.available2023-03-29T18:59:39Z-
dc.date.issued2021-
dc.identifier.issn0959-8049-
dc.identifier.urihttps://hdl.handle.net/10923/23949-
dc.language.isoen-
dc.relation.ispartofEUROPEAN JOURNAL OF CANCER-
dc.rightsopenAccess-
dc.titleA phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)-
dc.typeArticle-
dc.date.updated2023-03-29T18:59:38Z-
dc.identifier.doiDOI:10.1016/j.ejca.2021.08.032-
dc.jtitleEUROPEAN JOURNAL OF CANCER-
dc.volume158-
dc.spage63-
dc.epage71-
Appears in Collections:Artigo de Periódico



All Items in PUCRS Repository are protected by copyright, with all rights reserved, and are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Read more.